XOMA Co. (NASDAQ:XOMA) CIO Acquires $98,761.26 in Stock

XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko bought 4,134 shares of the company’s stock in a transaction on Friday, March 21st. The shares were bought at an average price of $23.89 per share, for a total transaction of $98,761.26. Following the completion of the acquisition, the executive now directly owns 10,484 shares in the company, valued at approximately $250,462.76. This trade represents a 65.10 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Bradley Sitko also recently made the following trade(s):

• On Wednesday, January 8th, Bradley Sitko acquired 313 shares of XOMA stock. The shares were bought at an average cost of $25.60 per share, with a total value of $8,012.80.
• On Tuesday, December 31st, Bradley Sitko acquired 300 shares of XOMA stock. The stock was bought at an average cost of $25.90 per share, for a total transaction of $7,770.00.

XOMA Stock Down 0.8 %

Shares of XOMA stock opened at $20.97 on Friday. The firm’s fifty day moving average price is $23.89 and its two-hundred day moving average price is $26.95. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 1 year low of $19.92 and a 1 year high of $35.00. The firm has a market capitalization of $251.20 million, a P/E ratio of -6.03 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last released its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. On average, equities analysts predict that XOMA Co. will post -1.41 EPS for the current fiscal year.

Institutional Investors Weigh In On XOMA

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its stake in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares in the last quarter. State Street Corp grew its position in shares of XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares during the period. Barclays PLC increased its stake in shares of XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 1,699 shares during the period. Institutional investors own 95.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on XOMA shares. HC Wainwright reissued a “buy” rating and issued a $104.00 price target on shares of XOMA in a research note on Wednesday, March 19th. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a report on Friday, March 21st.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.